Body weight alone is an unreliable proxy for metabolic health. Yet most weight-loss interventions are still evaluated by it. For clinicians managing patients with overweight or obesity, this matters: two patients can lose the same number of pounds and have entirely different outcomes, depending on what type of tissue they lost.
That distinction (fat loss versus lean mass loss) sits at the center of how Dr Terry Hall, a retired family practitioner, approached body composition in his own weight loss journey.
Fat Loss and Weight Loss Are Not the Same Thing
Weight loss can come from fat, non-fat tissue (including organs, bone, and muscle), or water. Fat loss specifically means reducing adipose tissue, not the non-fat tissue and water. With weight loss, organs may reduce in size, bones can become less minerally dense, and muscle mass may decrease. When patients lose muscle alongside fat, as commonly occurs with very-low-calorie or rapid weight-loss approaches, the consequences extend beyond aesthetics.
Lean muscle mass is metabolically active tissue. Its loss is associated with reduced resting energy expenditure, decreased insulin sensitivity, impaired physical function, and greater difficulty maintaining weight long-term.[1] For older patients in particular, muscle loss during weight reduction carries meaningful implications for mobility, fall risk, and healthy aging.[2]
This is why Dr. Hall argues that body composition, not body weight, should be the primary benchmark of a successful weight-loss program.
What a Structured, Composition-Focused Program Looks Like
According to Dr. Hall, sustainable fat loss with lean mass preservation requires more than a calorie deficit. Evidence-based programs typically combine four components working in concert:
- Appetite management: sustaining a calorie deficit long-term is one of the most significant adherence challenges patients face. Hunger dysregulation undermines even well-designed dietary plans.
- Adequate protein intake: protein supports satiety and provides the substrate required to maintain lean muscle mass during energy restriction.
- Resistance training: provides the anabolic stimulus that signals the body to preserve muscle tissue during weight reduction.
- Behavioral modification: addressing emotional eating, environmental food cues, and habitual triggers is often as clinically significant as nutrition and exercise intervention.
Research supports a slower, moderate-deficit approach rather than very-low-calorie restrictions, which have been associated with less weight loss (perhaps due to poor compliance).[3] Interestingly, however, lean mass loss (of which muscle mass is one component) across most diets is typically around 25% of the total weight lost, whether from very-low-calorie, low-calorie, low-fat or high-fiber diets.[4] In contrast, high-protein diets were associated with a lean mass loss of 11% of the total weight lost.[4]
Case Study: Body Composition Outcomes Over Four Months
Dr. Hall illustrated these principles in practice, using himself as a case study. As a 66-year-old retired physician, he had long-standing weight management difficulties: recurrent weight regain despite repeated diet and exercise attempts. Results of his baseline Dual X-ray Absorptiometry (DEXA) scan in April 2023 were:
- Weight: 255 lbs / 116 kg
- Body fat: 40.7%
- BMI: 31.0 kg/m² (Obesity Class 1)
- Visceral adipose tissue (VAT): 1,354 gm
Dr. Hall adopted a structured program combining the nutraceutical Calocurb for appetite management, a high-protein eating plan, daily walking averaging four miles (6.4 km), recreational activity (pickleball), resistance training, and behavioral strategies targeting emotional eating and social overeating triggers.
Four-Month DEXA Outcomes (April to August 2023)
Over the intervention period, Dr. Hall reduced his body weight from 255 lbs to 221 lbs (116 kg to 100 kg), a 13% reduction, at a rate of approximately 8–10 lbs (3.6–4.5 kg) per month.
DEXA analysis of that weight loss showed:
- 98% of weight loss came from fat mass (only 2% from muscle tissue)
- Body fat percentage decreased from 40.7% to 32.0% (a 21% decrease)
- VAT reduced from 1,354 gm to 964 gm (a 29% reduction)
- BMI shifted from 31.0 kg/m² to 26.9 kg/m² (moving from Obesity Class 1 to the Overweight category)
Dr. Hall describes his fat-to-lean mass loss ratio as exceptional. He attributes it to his consistent combination of resistance training and high-protein intake alongside effective appetite management — the latter achieved (where he'd failed in the past) through the use of Calocurb.
The Role of Appetite Management: How Calocurb Works
One of the most clinically relevant challenges in weight management is appetite dysregulation, the physiological drive to eat that intensifies under caloric restriction. This is where Calocurb's mechanism of action is relevant to clinical practice.
Calocurb contains Amarasate, a purified extract of New Zealand-grown hops developed by Plant & Food Research (PFR) over 15 years with $30 million in research investment. Amarasate activates bitter taste receptors (TAS2Rs) on enteroendocrine I- and L-cells in the small and large bowels, a pathway known as the "bitter brake." This stimulates endogenous release of glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), and peptide tyrosine tyrosine (PYY), all of which (either directly or indirectly) activate central nervous system loci for appetite and delay gastric emptying — resulting in increased satiety and satiation.
In a randomized, placebo-controlled crossover, clinical trial in healthy-weight men Amarasate produced an increase in baseline measurements of GLP-1 (6.4-fold), CCK (6.0-fold), and PYY (1.7-fold), with a subsequent reduction in calorie intake.[5] Furthermore, in 24-hour fasting studies in men and women, Amarasate resulted in significantly reduced overall hunger and cravings.[6,7]
Across three clinical trials in both men and women, Amarasate has demonstrated:
- 20% and 30% reductions in hunger in men and women, respectively[6,7]
- 40% reduction in cravings[7]
- 18% reduction in calorie intake[5]
More recently, Amarasate has demonstrated its effectiveness in a long-term weight loss study. In a 24-week, double-blind, placebo-controlled study of 150 people with overweight or obesity, the Amarasate recipients preserved their lean mass, gaining 0.9 kg of muscle while losing 4.5 kg of fat mass, for a total muscle-adjusted mean weight loss of 5.3% (p<0.01 vs. initial weight and vs. the placebo group).[8]
Calocurb's activation of TAS2Rs rather than stimulant pathways is why it does not carry the cardiovascular or anxiogenic side effects associated with caffeine-based appetite suppressants. This is a clinically relevant distinction for patients with hypertension or anxiety. In addition, because it's not a bulking agent, it doesn't typically cause gas, cramps or the bloating effects of high-fiber appetite suppressants.
Where Calocurb Fits in Clinical Practice
For practitioners navigating the growing patient demand for alternatives to GLP-1 receptor agonists (RAs), Calocurb occupies a distinct position. While it doesn't claim to produce the rapid and dramatic weight loss seen with GLP-1 RAs, it is an additional, effective non-prescription agent in the weight management toolbox. For patients who are not candidates for or decline GLP-1 medications, are seeking a natural-first approach, or are managing weight maintenance following a structured weight-loss phase, Calocurb offers a clinically validated, stimulant-free appetite management option supported by controlled trial evidence. It can also be used as a complementary product to GLP-1 RAs, allowing a reduction in dose of the prescription medication (with lower costs and fewer side effects), while helping maintain endogenous GLP-1 production — which is known to be blunted by GLP-1 RAs.[9]
As Dr. Hall notes, appetite management strategies play an important role in helping patients adhere to healthy eating patterns over time, particularly when combined with appropriate nutrition, resistance exercise, and behavioral support.
Measuring What Matters: DEXA as a Clinical Tool
This case also highlights the value of body composition monitoring beyond routine anthropometric measures. DEXA scanning provides discrimination between fat mass, lean mass, and bone density. It can also differentiate appendicular muscle mass, using appendicular lean mass (by measuring skeletal muscle in the limbs and bypassing internal organs, skin, connective tissue, and body water). Neither scales, BMI, nor waist circumference can provide this. In a patient achieving 13% weight loss, knowing that 98% of that loss was adipose tissue (including a 29% reduction in visceral fat), is clinically meaningful information that reinforces the value of the intervention and guides ongoing management.
Dr. Hall advocates for longitudinal body composition tracking in patients focused on long-term weight management goals, alongside monitoring of metabolic markers including blood pressure and fasting glucose.
